NEW YORK (GenomeWeb News) – Manhattan Labs will market CombiMatrix's chromosomal microarray testing services to customers in the New York City metropolitan area, the firms said today.

Manhattan Labs CEO Ken Cerney said in a statement that the independent clinical laboratory opted to offer the test as part of a new focus on miscarriage management, and added that his firm "believes in the growing importance and clinical advantages microarray testing provides for appropriate patients."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Polygamy amplified a rare genetic disease in area near Arizona-Utah border, BBC Future reports.

Genetic ancestry testing led one woman to learn that her father and another baby boy had been switched at birth, the Washington Post reports.

Simple de-identification methods can protect information in a database from attackers, a new study suggests.

In Science this week: approach to visualize chromatin structure in nuclei, and more.